KPTI vs SPCE · rev $68.5M vs rev $361.0K
Karyopharm Therapeutics Inc (KPTI) versus Virgin Galactic Holdings Inc (SPCE) — a side-by-side from cached financials, not a winner call.
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
Virgin Galactic Holdings Inc (SPCE) is a aerospace & defense company listed on NYSE.
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
Latest reported SPCE revenue for 2026-06-30 was $361.0K. Net income was -$120.6M. Revenue was up 59.0% from 2026-03-31 to 2026-06-30. SPCE currently screens at market cap $388.0M.
KPTI currently screens at market cap $205.6M. SPCE currently screens at market cap $388.0M.
Not investment advice. Open the KPTI and SPCE stock pages for the full models.
Not investment advice.